{"filing":{"accession_number":"0001683168-26-005899","cik":"0001402328","ticker":"SBFMW","company_name":"Sunshine Biopharma Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"sunshine_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826005899/sunshine_8k.htm"},"events":[{"id":23450,"run_id":21201,"accession_number":"0001683168-26-005899","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses recent sales of common stock under a previously disclosed at-the-market (ATM) offering, which triggered a downward adjustment of the exercise price of outstanding Series B Warrants from an unstated prior level to $1.2202. ATM offerings are a form of dilutive equity issuance commonly disclosed under Item 3.02, and the warrant repricing mechanism indicates material dilution to existing security holders. While the disclosure is brief and filed under Item 8.01, the substance is a dilutive equity capital raise.","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23672,"accession_number":"0001683168-26-005899","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses recent sales of common stock under a previously disclosed at-the-market (ATM) offering, which triggered a downward adjustment of the exercise price of outstanding Series B Warrants from an unstated prior level to $1.2202. ATM offerings are a form of dilutive equity issuance commonly disclosed under Item 3.02, and the warrant repricing mechanism indicates material dilution to existing security holders. While the disclosure is brief and filed under Item 8.01, the substance is a dilutive equity capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:32:42.417464+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23672,"accession_number":"0001683168-26-005899","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses recent sales of common stock under a previously disclosed at-the-market (ATM) offering, which triggered a downward adjustment of the exercise price of outstanding Series B Warrants from an unstated prior level to $1.2202. ATM offerings are a form of dilutive equity issuance commonly disclosed under Item 3.02, and the warrant repricing mechanism indicates material dilution to existing security holders. While the disclosure is brief and filed under Item 8.01, the substance is a dilutive equity capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:32:42.417464+00:00","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-08-03"}]}